BACKGROUND: This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …

Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …

7077 Background: Previous clinical trials have revealed that gefitinib is more likely to be
effective in non-small cell lung cancer (NSCLC) with activating somatic mutations of …

PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …

The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …

7183 Purpose: Recent studies have indicated that the mutations of epidermal growth factor
receptor (EGFR) were associated with sensitivity of non-small cell lung cancer (NSCLC) to …

Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …

Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …

Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …

Introduction: We evaluated the efficacy of gefitinib monotherapy prospectively in patients
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …